134 related articles for article (PubMed ID: 7717688)
1. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype.
Nitsch RM; Rebeck GW; Deng M; Richardson UI; Tennis M; Schenk DB; Vigo-Pelfrey C; Lieberburg I; Wurtman RJ; Hyman BT
Ann Neurol; 1995 Apr; 37(4):512-8. PubMed ID: 7717688
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
3. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
5. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease.
Harrington CR; Louwagie J; Rossau R; Vanmechelen E; Perry RH; Perry EK; Xuereb JH; Roth M; Wischik CM
Am J Pathol; 1994 Dec; 145(6):1472-84. PubMed ID: 7992850
[TBL] [Abstract][Full Text] [Related]
6. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
Motter R; Vigo-Pelfrey C; Kholodenko D; Barbour R; Johnson-Wood K; Galasko D; Chang L; Miller B; Clark C; Green R
Ann Neurol; 1995 Oct; 38(4):643-8. PubMed ID: 7574461
[TBL] [Abstract][Full Text] [Related]
7. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
Ewers M; Zhong Z; Bürger K; Wallin A; Blennow K; Teipel SJ; Shen Y; Hampel H
Brain; 2008 May; 131(Pt 5):1252-8. PubMed ID: 18334538
[TBL] [Abstract][Full Text] [Related]
8. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
[TBL] [Abstract][Full Text] [Related]
10. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
11. CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type.
Fellgiebel A; Kojro E; Müller MJ; Scheurich A; Schmidt LG; Fahrenholz F
J Geriatr Psychiatry Neurol; 2009 Mar; 22(1):3-9. PubMed ID: 19073834
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease.
Gomez-Isla T; West HL; Rebeck GW; Harr SD; Growdon JH; Locascio JJ; Perls TT; Lipsitz LA; Hyman BT
Ann Neurol; 1996 Jan; 39(1):62-70. PubMed ID: 8572669
[TBL] [Abstract][Full Text] [Related]
13. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype.
Fagan AM; Younkin LH; Morris JC; Fryer JD; Cole TG; Younkin SG; Holtzman DM
Ann Neurol; 2000 Aug; 48(2):201-10. PubMed ID: 10939571
[TBL] [Abstract][Full Text] [Related]
14. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.
Noguchi M; Yoshita M; Matsumoto Y; Ono K; Iwasa K; Yamada M
J Neurol Sci; 2005 Oct; 237(1-2):61-5. PubMed ID: 15992827
[TBL] [Abstract][Full Text] [Related]
15. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
16. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.
Wiltfang J; Esselmann H; Bibl M; Hüll M; Hampel H; Kessler H; Frölich L; Schröder J; Peters O; Jessen F; Luckhaus C; Perneczky R; Jahn H; Fiszer M; Maler JM; Zimmermann R; Bruckmoser R; Kornhuber J; Lewczuk P
J Neurochem; 2007 May; 101(4):1053-9. PubMed ID: 17254013
[TBL] [Abstract][Full Text] [Related]
17. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
[TBL] [Abstract][Full Text] [Related]
18. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease.
Nakamura T; Shoji M; Harigaya Y; Watanabe M; Hosoda K; Cheung TT; Shaffer LM; Golde TE; Younkin LH; Younkin SG
Ann Neurol; 1994 Dec; 36(6):903-11. PubMed ID: 7998778
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein.
Polvikoski T; Sulkava R; Haltia M; Kainulainen K; Vuorio A; Verkkoniemi A; Niinistö L; Halonen P; Kontula K
N Engl J Med; 1995 Nov; 333(19):1242-7. PubMed ID: 7566000
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
Maruyama M; Arai H; Sugita M; Tanji H; Higuchi M; Okamura N; Matsui T; Higuchi S; Matsushita S; Yoshida H; Sasaki H
Exp Neurol; 2001 Dec; 172(2):433-6. PubMed ID: 11716567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
